SEATTLE, May 23, 2018 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global dementia drugs market was valued US$ 13.90 Billion in 2017 and is projected to exhibit a CAGR of 8.4% over the forecast period (2018 – 2026).
Click the link below, to know more insights in this market:
https://www.coherentmarketinsights.com/market-insight/dementia-drugs-market-1664
Key Trends and Analysis of Dementia Drugs Market:
The global dementia drugs market is expected to witness significant growth over the forecast period, owing to increasing incidence of dementia worldwide, especially in Asian countries such as China, India, Japan, and Korea along with increasing launch of pipeline drugs. Approvals and launches of first-in-class BACE1 inhibitors and passive immunotherapies between 2018 and 2020, are expected to drive growth of the dementia market, as several blockbuster drugs are expected to result from these two potentially disease-modifying therapeutic classes. Furthermore, BACE1 inhibitors may face competition from anticipated launch of experimental monoclonal antibodies (mAbs) - Biogen’s aducanumab, Eli Lilly’s solanezumab and Roche’s gantenerumab and crenezumab during the forecast period.
Improving diagnostic technologies and updated diagnostic guidelines are expected to support growth of the dementia market. For instance, in 2012, commercial launch of Eli Lilly’s Amyvid, the first beta imaging agent indicated for Positron Emission Tomography (PET) imaging of the brain, enhanced the value of Alzheimer Disease (AD) diagnostic agents to improve long-term health outcomes. This test determines beta-amyloid neuritic plaque density among adult patients suffering from cognitive impairment for AD.
Request Sample Copy of this Report
Key Takeaways:
- The global dementia drugs market is expected to expand at a CAGR of 8.4% during the forecast period (2018 –2026), owing to introduction of innovative drugs with higher efficacy toward dementia patients and increasing government initiatives to provide better palliative care to patients
- The MAO inhibitors segment is expected to gain significant traction over the forecast period, as monoamine oxidase-B (MAO-B) inhibitor is less toxic than cholinesterase inhibitor and has a concomitant extension of life span
- Some of the major players in the global dementia drugs market include Eisai, Inc., Janssen Pharmaceuticals, Inc., Biogen Pharmaceuticals, Forest Laboratories, Inc., Eli Lilly and Company, Novartis AG, Sanofi S.A., AstraZeneca GmbH, F. Hoffmann-La Roche, Merck & Co., Valeant Pharmaceutical International, Pfizer Inc., and Teva Pharmaceuticals Industries Ltd.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave.
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com